Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy
Cancer Medicine · 2024
DOI: 10.1002/cam4.7464 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Aasha I Hoogland und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Ipilimumab, Nivolumab, Carcinoma, Merkel Cell, Quality of Life. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Bristol Myers Squibb Rare Population Malignancy Program.
Abstract (Originalsprache)
Background
Merkel cell carcinoma is a rare skin cancer associated with poor survival. Based on a previous Phase II trial of adults with advanced Merkel cell carcinoma by Kim and colleagues (2022), there is now a strong rationale for combination therapy (i.e., nivolumab and ipilimumab) to become a treatment option for patients with advanced Merkel cell carcinoma. The goal of this paper was to report on the secondary outcome of quality of life (QOL) among patients on this trial.
Methods
Patients receiving combined nivolumab and ipilimumab, with or without stereotactic body radiation therapy (SBRT), completed the European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 prior to starting treatment and every 2 weeks thereafter. Changes in QOL during treatment and post‐treatment were evaluated using piecewise random‐effects mixed models. Exploratory analyses compared changes in QOL between study arms. The original trial was registered with ClinicalTrials.gov (NCT03071406).
Results
Study participants ( n = 50) reported no changes in overall QOL ( p s > 0.05), but emotional functioning improved during treatment ( p = 0.01). Cognitive and social functioning worsened post‐treatment ( p s < 0.01). In general, patients treated with combination therapy only ( n = 25) reported no change in QOL over time, whereas patients also treated with SBRT ( n = 25) consistently demonstrated worsening QOL post‐treatment.
Conclusion
QOL is generally preserved in patients treated with combination therapy, but the addition of SBRT may worsen QOL. Combined with clinical efficacy data published previously, results support the use of combination therapy with nivolumab and ipilimumab as a treatment option for patients with advanced Merkel cell carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- School of Aging Studies, University of South Florida, Tampa, Florida, USA.
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Radiation Oncology, Ohio State University, Columbus, Ohio, USA.
- Department of Cutaneous Oncology, Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Aasha I Hoogland, Heather S L Jim
Förderung
- NCI NIH HHS
- Bristol Myers Squibb Rare Population Malignancy Program
Zitieren
APA
Hoogland, A. I., Brohl, A. S., Small, B. J., Michael, L., Wuthrick, E., Eroglu, Z., Blakaj, D., Verschraegen, C., Khushalani, N. I., Jim, H. S. L., & Kim, S. (2024). Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy. Cancer Medicine. https://doi.org/10.1002/cam4.7464
Vancouver
Hoogland AI, Brohl AS, Small BJ, Michael L, Wuthrick E, Eroglu Z, et al. Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy. Cancer Medicine. 2024. doi:10.1002/cam4.7464
BibTeX
@article{Hoogland2024,
author = {Hoogland, Aasha I and Brohl, Andrew S and Small, Brent J and Michael, Lauren and Wuthrick, Evan and Eroglu, Zeynep and Blakaj, Dukagjin and Verschraegen, Claire and Khushalani, Nikhil I and Jim, Heather S L and Kim, Sungjune},
title = {Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7464}
}
EUVIMED